Sort
15,273 grants matching “antimicrobial resistance”
Task X11: Product Development Plans and Feasibility Assessments
$106,884James Richardson · Advanced Bioscience Laboratories, Inc. · N01 · FY2015 · AI
Prevention of Adult Caries (PACS) - Tufts Administrative Center
$106,780Athena S. Papas · Tufts University Boston · U01 · FY2009 · DE
PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST H PYLORI IN RHESUS MACAQUES
$106,671Jay V. Solnick · University Of California At Davis · P51 · FY2009 · RR
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter baumannii
$106,500Maria Soledad Ramirez · California State University Fullerton · SC3 · FY2020 · GM
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter spp
$106,500Maria Soledad Ramirez · California State University Fullerton · SC3 · FY2022 · GM
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter baumannii
$106,500Maria Soledad Ramirez · California State University Fullerton · SC3 · FY2019 · GM
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter spp
$106,500Maria Soledad Ramirez · California State University Fullerton · SC3 · FY2023 · GM
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter baumannii
$106,500Maria Soledad Ramirez · California State University Fullerton · SC3 · FY2021 · GM
Targeting Non-mammalian Isoprenoid Biosynthesis
$106,438Caren L. Freel Meyers · Johns Hopkins University · R01 · FY2019 · GM
DEVELOPMENT OF A REPRESSOR BASED SCREEN FOR ANTIBIOTICS
$106,166Advanced Microbial Solutions Corporation · R43 · FY2000 · AI
Understanding polymer-induced bacterial aggregation and antimicrobial tolerance
$106,024Patrick R Secor · University Of Montana · K22 · FY2019 · AI
CONSEQUENCES OF GROUP B STREPTOCOCCAL PROPHYLAXIS
$105,840Brigham And Women'S Hospital · K23 · FY2004 · AI
METALLO BETA LACTAMASE FROM X MALTOPHILIA
$105,832Miami University Oxford · R29 · FY2001 · AI
Bacteriophages as Modulators of Bacterial Colonization
$105,792Lynn El Haddad · University Of Florida · K01 · FY2024 · AI
Bacteriophages as Modulators of Bacterial Colonization
$105,792Lynn El Haddad · University Of Florida · K01 · FY2025 · AI
Bacteriophages as Modulators of Bacterial Colonization
$105,792Lynn El Haddad · University Of Florida · K01 · FY2022 · AI
Bacteriophages as Modulators of Bacterial Colonization
$105,792Lynn El Haddad · University Of Florida · K01 · FY2023 · AI
Cutaneous Host Defense Against Bacterial Infections
$105,678Lloyd S Miller · University Of California Los Angeles · K08 · FY2006 · AI
Containing Bioterroist and Emerging Infectious Diseases
$105,600Ira M Longini · Fred Hutchinson Cancer Research Center · U01 · FY2008 · GM
VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT
$105,346David Bush · University Of Iowa · N01 · FY2017 · AI
Task A15: In vitro screening for antibacterial activity against public health disease pathogens
$105,220Thomas Patterson · University Of Texas Hlth Science Center · N01 · FY2021 · AI
Evolution of Pseudomonas aeruginosa in premise plumbing and impact on cystic fibrosis respiratory disease pathogenesis
$105,213Catherine Rebecca Armbruster · Carnegie-Mellon University · K22 · FY2025 · AI
Anthrax Immune Globulin to Prevent & Treat Anthrax: Advanced Product Development
$105,204Ajoy Chakrabarti · Emergent Product Development Gaithersbur · U01 · FY2008 · AI
Biocidal Dendrimers for Novel Antimicrobial Surfaces
$105,180Lynntech, Inc. · R43 · FY2002 · AI
Chicago Prevention and Intervention Epicenter (Chicago PIE)
$105,000Robert Alan Weinstein · Hektoen Institute For Medical Research · U54 · FY2014 · CK